Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until
recently, there were limited therapeutic options. However, over the last decade our …

The use of inhibitors of vascular endothelial growth factor (VEGF)/vascular endothelial
growth factor receptor 2 (VEGFR2) signaling for the treatment of cancer has increased over …

Background: Management of patients with advanced medullary thyroid cancer (MTC)
remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) vandetanib and …

Rearranged during transfection (RET) is a receptor tyrosine kinase essential for the normal
development and maturation of a diverse range of tissues. Aberrant RET signaling in …

Context Radioiodine refractory differentiated thyroid cancer (RAIR-DTC) has been a global
challenge due to its poor prognosis and limited treatment options. Objective We report here …

Simple Summary Angiogenesis is an essential event for the progression of solid tumors and
is promoted by angiogenic cytokines released in the tumor microenvironment by neoplastic …

Over the past decade, the prognosis of advanced thyroid cancer (TC) patients has
dramatically improved thanks to the introduction of tyrosine kinase inhibitors (TKIs). Despite …

Cancer is one of the leading causes of death worldwide. Chemotherapy-induced arrhythmia
is a potential complication of treatment that confers increased morbidity and mortality. The …

The kinase-inhibitors (KIs) sorafenib and lenvatinib demonstrated efficacy in iodine-
refractory DTC upon phase III studies. However, evidence allowing a punctual balance of …

Simple Summary In patients with advanced radioiodine refractory differentiated thyroid
carcinoma (DTC), therapeutic options are limited. In the “Study of (E7080) Lenvatinib in …